Latest news with #Visterra
Yahoo
15-07-2025
- Business
- Yahoo
Otsuka to acquire Cantargia's CAN10 for autoimmune diseases
Otsuka Pharmaceutical has signed an agreement to acquire all assets related to Cantargia's early-clinical stage CAN10 programme, an antibody in development as a drug candidate for autoimmune diseases. CAN10 targets interleukin-1 receptor accessory protein (IL1RAP) with potent inhibitory effects on pro-inflammatory cytokines within the interleukin 1 (IL-1) superfamily — IL-1, IL-33 and IL-36 — which are associated with various inflammatory or autoimmune diseases. Cantargia will receive a $33m upfront cash payment and up to an additional $580m in milestone payments, along with double-digit tiered earn-out payments from worldwide product sales. The transaction is subject to customary closing conditions and regulatory approval, with expectations set for completion in the third quarter of 2025. Otsuka Pharmaceutical president and representative director Makoto Inoue stated: "Otsuka Pharmaceutical is expanding its research and development pipeline in the field of autoimmune diseases by leveraging the antibody drug platform of our US subsidiary, Visterra, and the low-molecular-weight drug discovery platform of our US subsidiary Jnana Therapeutics. 'This will further expand and accelerate our research and development portfolio targeting various pathways associated with autoimmune diseases, enabling us to contribute to the lives of more patients." Otsuka Pharmaceutical will take full responsibility for developing and commercialising CAN10 across the globe. This entails directing all future development activities, seeking regulatory approvals, as well as exclusively managing manufacturing and sales operations worldwide. Otsuka Pharmaceutical also gains access to 3G5, a backup antibody. CAN10 is currently in a Phase I clinical trial. Cantargia interim CEO Damian Marron stated: 'This is a transformative transaction for Cantargia, and we hope for millions of patients suffering from severe immune-inflammatory disorders. 'We are delighted that the strong potential of our CAN10 anti-IL1RAP antibody has been recognised by Otsuka Pharmaceutical. It demonstrates confidence in the strength of our world-leading position in IL1RAP biology and antibodies and will allow us to drive forward our platforms and programs in oncology and other diseases.' "Otsuka to acquire Cantargia's CAN10 for autoimmune diseases" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
12-06-2025
- Business
- Yahoo
Nona Biosciences and Visterra Partner to Advance Next-Generation Biotherapeutics for Immune-Mediated and Autoimmune Diseases
CAMBRIDGE, Mass., June 12, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced a license agreement with Visterra, Inc. to advance Visterra's next-generation biotherapeutic pipeline for immune-mediated and autoimmune diseases, leveraging Nona's proprietary HCAb Harbour Mice® technology platform. Nona's HCAb Harbour Mice® platform enables the generation of fully human heavy-chain-only antibodies (HCAbs), offering key advantages such as reduced immunogenicity and enhanced versatility for next-generation biotherapeutics. This innovative platform has been clinically validated and widely recognized by global partners. "We are pleased to collaborate with Visterra and support the development of their biotherapeutic pipeline," said Jingsong Wang, MD, PhD, Chairman of Nona Biosciences. "This collaboration reflects our commitment to advancing biotherapeutic innovation. By leveraging our fully human HCAbs, we aim to unlock new therapeutic possibilities and accelerate the development of transformative medicines for patients worldwide." About Nona Biosciences Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing integrated solutions from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team. Harbour Mice® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit: About Visterra Visterra is a biologics research and early-stage clinical development biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with immune-mediated kidney diseases and other hard-to-treat diseases. For more information, please visit: View original content to download multimedia: SOURCE Nona Biosciences Sign in to access your portfolio
Yahoo
01-04-2025
- Business
- Yahoo
Visterra Expands Reach Into Northern Ohio, Western Pennsylvania, Northeast Indiana With Acquisition of Leading Commercial Landscape and Snow Service Provider, H&M Landscaping
Partnership with H&M marks Visterra's second acquisition of 2025, highlighting the company's commitment to investing in best-in-class organizations capable of delivering a full suite of landscaping services to clients across the fast-growing platform CHICAGO, IL / / April 1, 2025 / Visterra Landscape Group, the premier commercial landscaping platform, today announced the acquisition of Cleveland-based H&M Landscaping (H&M), one of northern Ohio's leading commercial landscape and snow and ice management service providers. The partnership with H&M extends Visterra's service reach across Ohio, western Pennsylvania and northeast Indiana. H&M Landscape was founded in 1988 by CEO Mark Mazzurco and has long been recognized as an award winning service provider of complex landscaping and snow services, earning more than two dozen high-profile accolades. The company is home to nearly 300 employees and supported by a leadership team with more than a century of combined experience in operational and client service excellence. All H&M employees, including Mazzurco and his leadership team, will remain with Visterra in mission critical positions as the company embarks on the next chapter of growth, service excellence, and providing employees career advancement opportunities within the Visterra platform. "Our history, reputation and legacy are tied to the hard work, passion and dedication of our people who have made H&M what we are today, and I couldn't be more proud of everything we have accomplished over the last four decades," Mazzurco said. "It has been the honor of a lifetime to serve the incredible people and organizations throughout all of northern Ohio including our employees, customers and other stakeholders who have been with us from our humble beginnings. While the decision to enter the next chapter of our lifecycle was not easy, I am confident the partnership with Visterra will create significant value for our people, customers and legacy." Visterra Chief Executive Officer Alan Handley attributed H&M's success, and synergy with Visterra, to an alignment of shared values, and in particular, an employee-first culture and commitment to exceptional customer experiences. "Mark's leadership, vision and passion have guided H&M's success over many decades, earning H&M a reputation as one of the most respected and successful commercial landscaping and snow and ice management providers in greater Cleveland and northern Ohio," Handley said. "We are absolutely thrilled to welcome Mark and all H&M employees and customers to the Visterra family. Together, we will continue to forge a culture that prioritizes employee wellbeing and customer satisfaction as we expand across the region and into new markets." The acquisition of H&M Landscaping is Visterra's second in 2025, and seventh since its founding in 2022. Visterra was represented by legal counsel Much Shelist and the transaction is effective immediately. No financial terms were disclosed. Founders and owners of commercial landscaping businesses interested in a partnership with Visterra may send an email to inquiry@ or visit ABOUT VISTERRA LANDSCAPE GROUP Visterra Landscape Group is the premier commercial landscaping platform, ranking among the largest landscape service providers and the 12th largest snow and ice removal companies in North America. In 2024, Visterra was named a Lawn & Landscape Best Places to Work winner and recognized with multiple safety excellence awards by the National Association of Landscape Professionals. Visterra partner companies safely deliver expert landscape maintenance, enhancement, construction, lot sweeping, portering and snow and ice removal services with a reputation for excellence in customer service. With incumbent partner leaders guiding day-to-day operations, Visterra continues to grow its platform with a team that prioritizes employee well-being, safety, and career opportunities. Visterra partner companies include Riverside Services in the Northeast; Dyna-Mist in the South, and Oberson's, GroundsPRO, Full Care, Cru Cutters and H&M Landscaping serving the greater Midwest. For more information visit ### Contacts: Media: media@ | M&A: inquiry@ SOURCE: Visterra Landscape Group View the original press release on ACCESS Newswire Sign in to access your portfolio
